Insider Transactions in Q3 2022 at Optimize Rx Corp (OPRX)
Insider Transaction List (Q3 2022)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 29
2022
|
Patrick D Spangler Director |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+1.99%
|
-
|
Sep 29
2022
|
Gregory D Wasson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+1.8%
|
-
|
Sep 29
2022
|
Ellen O'Connor Vos Director |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+0.98%
|
-
|
Sep 29
2022
|
James Paul Lang Director |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+0.85%
|
-
|
Sep 29
2022
|
Gus D Halas Director |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+0.51%
|
-
|
Aug 26
2022
|
Marion Odence Ford General Counsel and CCO |
BUY
Open market or private purchase
|
Direct |
1,000
+16.67%
|
$15,000
$15.75 P/Share
|
Aug 22
2022
|
William J Febbo CEO |
BUY
Open market or private purchase
|
Direct |
10,700
+2.26%
|
$160,500
$15.29 P/Share
|
Aug 19
2022
|
James Paul Lang Director |
BUY
Open market or private purchase
|
Direct |
6,000
+13.43%
|
$96,000
$16.45 P/Share
|
Aug 19
2022
|
William J Febbo CEO |
BUY
Open market or private purchase
|
Direct |
5,400
+1.18%
|
$86,400
$16.18 P/Share
|
Aug 16
2022
|
Stephen L Silvestro Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
3,200
+50.0%
|
$48,000
$15.66 P/Share
|
Aug 16
2022
|
Ellen O'Connor Vos Director |
BUY
Open market or private purchase
|
Direct |
500
+50.0%
|
$7,500
$15.91 P/Share
|
Aug 15
2022
|
Edward Stelmakh CFO/COO |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$45,000
$15.43 P/Share
|